Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program
– Clinical trial to enroll patients with early-stage Multiple Systems Atrophy (MSA) – – Expanding bioMUSE Natural History
Read More
We exist to create an alternate future for people with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory for people living with these debilitating diseases.
First-in-class therapies to treat neurodegenerative disease
Alterity is developing first-in-class therapies to treat neurodegenerative disease. Our lead drug candidate, ATH434, has demonstrated efficacy in several animal models of Parkinsonian disorders and is being evaluated in clinical trials.
News
Presentation of New Biomarker Data at Scientific Congress
Study Results Successfully Inform the Design of ATH434 Phase 2 Clinical Trial Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity”
Read More
Receive news from Alterity Therapeutics
